Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19
- 1 January 2006
- journal article
- review article
- Published by Elsevier BV in Psychosomatics
- Vol. 47 (1), 75-85
- https://doi.org/10.1176/appi.psy.47.1.75
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Why clinicians are natural bayesiansBMJ, 2005
- Clinical Pharmacokinetics of AtomoxetineClinical Pharmacokinetics, 2005
- Integrating pharmacogenetics into society: in search of a modelNature Reviews Genetics, 2004
- Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio,CYP2D6andCYP2C9Genotypes in Psychiatric PatientsPharmacopsychiatry, 2004
- CYP2C19- and CYP3A4-Dependent Omeprazole Metabolism in West MexicansThe Journal of Clinical Pharmacology, 2003
- Pharmacogenetics to comeNature, 2003
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Pharmacogenetics and pharmacogenomicsBritish Journal of Clinical Pharmacology, 2001
- Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylationBritish Journal of Clinical Pharmacology, 1999
- The Runners-UpScience, 1997